Hepatoblastoma. Clinical experience at a single institution using the Siopel staging system

被引:5
作者
Leal-Leal, Carlos A. [1 ]
Imaz-Olguin, Victoria [1 ]
Robles-Castro, Julieta [1 ]
Shalkow-Klinc'ovstein, Jaime [2 ]
Palacios-Acosta, Jose M. [2 ]
机构
[1] Inst Nacl Pediat, Dept Med Oncol, Mexico City 04530, DF, Mexico
[2] Inst Nacl Pediat, Dept Surg Oncol, Mexico City 04530, DF, Mexico
关键词
Hepatoblastoma; Tumor volume; Prognosis; INTERNATIONAL SOCIETY; BIRTH-WEIGHT; RISK-FACTORS; CHILDREN;
D O I
10.1016/S1665-2681(19)31683-7
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background. Staging in Hepatoblastoma has recently become controversial. In developing countries diagnosis occurs mostly in advanced stages under these circumstances, we propose another option that can be considered of prognostic value. Method. A retrospective analysis of cases diagnosed with Hepatoblastoma (HB), treated in a single Institution, in nine years was conducted. Chemotherapeutic regimens were analyzed, as well as the number of courses administered and response to treatment. Results. Thirty-two patients were studied. Patients had symptoms from 1 to 25 weeks before diagnosis. SIOP stratification was used, finding 12 cases in PRETEXT II, 6 cases in PRETEXT III, and 14 cases in PRETEXT IV. No single case was identified in PRETEXT I. Conclusions. When comparing survival using the PRETEXT system, SIOP and our study showed marked differences. These results may not be comparable due to differences in tumor volume among the same PRETEXT stratification. We believe that tumor volume is related to prognosis.
引用
收藏
页码:75 / 79
页数:5
相关论文
共 14 条
[1]   Predictive value of the pretreatment extent of disease system in hepatoblastoma: Results from the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 Study [J].
Aronson, DC ;
Schnater, JM ;
Staalman, CR ;
Weverling, GJ ;
Plaschkes, J ;
Perilongo, G ;
Brown, J ;
Phillips, A ;
Otte, JB ;
Czauderna, P ;
MacKinlay, G ;
Vos, A .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) :1245-1252
[2]   Pretreatment prognostic factors for children with hepatoblastoma results from the International Society of Paediatric Oncology (SIOP) Study SIOPEL 1 [J].
Brown, J ;
Perilongo, G ;
Shafford, E ;
Keeling, J ;
Pritchard, J ;
Brock, P ;
Dicks-Mireaux, C ;
Phillips, A ;
Vos, A ;
Plaschkes, J .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (11) :1418-1425
[3]  
BUCKLEY JD, 1989, CANCER-AM CANCER SOC, V64, P1169, DOI 10.1002/1097-0142(19890901)64:5<1169::AID-CNCR2820640534>3.0.CO
[4]  
2-I
[5]  
Herzog C E, 2000, Oncologist, V5, P445, DOI 10.1634/theoncologist.5-6-445
[6]  
LEAL C, 2006, HEMATO ONCOLOGIA PED, P451
[7]  
MEYERS RL, 2009, PEDIAT BLOOD CANC
[8]   Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group [J].
Ortega, JA ;
Douglass, EC ;
Feusner, JH ;
Reynolds, M ;
Quinn, JJ ;
Finegold, MJ ;
Haas, JE ;
King, DR ;
Liu-Mares, W ;
Sensel, MG ;
Krailo, MD .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (14) :2665-2675
[9]   Hepatoblastoma in children of extremely low birth weight: A report from a single perinatal center [J].
Oue, T ;
Kubota, A ;
Okuyama, H ;
Kawahara, H ;
Nara, K ;
Kawa, K ;
Kitajima, H .
JOURNAL OF PEDIATRIC SURGERY, 2003, 38 (01) :134-137
[10]   Risk-adapted treatment for childhood hepatoblastoma:: final report of the second study of the International Society of Paediatric Oncology-SIOPEL 2 [J].
Perilongo, G ;
Shafford, E ;
Maibach, R ;
Aronson, D ;
Brugières, L ;
Brock, P ;
Childs, M ;
Czauderna, P ;
MacKinlay, G ;
Otte, JB ;
Pritchard, J ;
Rondelli, R ;
Scopinaro, M ;
Staalman, C ;
Plaschkes, J .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (03) :411-421